# The Role of Gamma Knife Surgery in the Treatment of Rare Sellar Neoplasms: A Report of Nine Cases

**Authors:** Michele Longhi, Riccardo Lavezzo, Valeria Barresi, Giorgia Bulgarelli, Anna D’Amico, Antonella Lombardo, Emanuele Zivelonghi, Paolo Maria Polloniato, Giuseppe Kenneth Ricciardi, Francesco Sala, Angelo Musumeci, Giampietro Pinna, Antonio Nicolato

PMC · DOI: 10.3390/cancers17091564 · 2025-05-03

## TL;DR

Gamma Knife Surgery is shown to be a safe and effective treatment for rare sellar-region tumors, based on a study of nine patients with varied diagnoses.

## Contribution

This is the largest reported series of rare sellar lesions treated with Gamma Knife Radiosurgery at a single center.

## Key findings

- All nine patients showed favorable clinical and radiological responses after Gamma Knife Radiosurgery.
- Gamma Knife Surgery demonstrated very low toxicity in treating rare sellar-region lesions.
- The study suggests Gamma Knife Surgery could be an effective non-invasive treatment option for these rare tumors.

## Abstract

This study evaluated the long-term outcomes of Gamma Knife Radiosurgery (GKRS) in treating rare sellar-region lesions at a single high-volume center. Nine patients treated between 2004 and 2015 were retrospectively analyzed. The lesions included hypothalamic hamartoma, Rathke’s cleft cyst, Langerhans cell histiocytosis, spindle cell oncocytoma, choroid plexus papilloma, and ossifying fibroma. Diagnosis was histologically confirmed in six patients, while three were diagnosed based on clinical and radiological features. All cases showed favorable clinical and radiological responses after GKRS, with very low toxicity. These findings suggest that GKRS is a safe and effective non-invasive treatment option even for rare sellar lesions. This represents the largest reported series of such cases treated with GKRS. However, further studies with larger patient cohorts are needed to determine if GKRS offers benefits over the natural course or other non-invasive therapies.

Introduction: The group of so-called “sellar-region masses” consists of a heterogeneous group of neoplasms and tumor-mimicking lesions, whose differential diagnosis may be challenging due to the overlapping of clinical and radiological features, which can be found both in “common” and “uncommon” lesions. The choice of a correct treatment strategy is still arduous and requires histological analysis. Gamma Knife Radiosurgery (GKRS) has already been reported as a safe and effective treatment in these cases. The objective of this study is to evaluate single-center pre-operative data, post-operative outcomes, and long-term follow-up in patients treated with GKRS for unusual sellar tumors. Methods: We retrospectively identified and analyzed nine patients treated with GKRS from 2004 to 2015, according to a standard protocol. Lesions consist of hypothalamic hamartoma (HH), Rathke’s cleft cist (RCC), Langerhans cell histiocytosis (LCH), spindle cell oncocytoma (SCO), choroid plexus papilloma (CPP), and ossifying fibroma (OF). The diagnosis was histologically confirmed in six patients that underwent surgery, while in three patients, diagnosis was based on characteristic clinical and radiological findings (two HH and one RCC). Pre-operative and post-operative data were retrieved from medical archives, and long-term follow-up was obtained through clinical and neuroradiological periodic examination. Results: In our series, all the “rare” sellar lesions treated, had a successful radiographic and clinical response in a medium-long follow-up period. Conclusions: The long-term follow-up results suggest that GKRS is a safe and effective treatment in rare sellar lesions, with very low toxicity. To the best of our knowledge, this report represents the largest series of unusual sellar lesions treated with GKRS in a single high-volume center, suggesting that GKRS might be an effective non-invasive adjuvant treatment option. Further studies and a larger number of patients are needed to confirm if residuals of these rare sellar lesions might regress on their own without treatment or if other non-invasive treatments could be as effective as GKRS.

## Linked entities

- **Diseases:** hypothalamic hamartoma (MONDO:0009436), Langerhans cell histiocytosis (MONDO:0017025), spindle cell oncocytoma (MONDO:0858960), choroid plexus papilloma (MONDO:0009837), ossifying fibroma (MONDO:0002119)

## Full-text entities

- **Diseases:** LCH (MESH:D006646), toxicity (MESH:D064420), HH (MESH:C537158), sellar lesions (MESH:D009059), RCC (MESH:D020863), CPP (MESH:D020288), Sellar Neoplasms (MESH:D009369), OF (MESH:D018214), SCO (MESH:C537750), sellar-region masses (MESH:C536030)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12072044/full.md

---
Source: https://tomesphere.com/paper/PMC12072044